Park Nicollet Clinic - Saint Louis Park — Biomedical Watch V2

Essais liés17clinical trials

VilleSaint Louis Parklocalisation

PaysUnited Stateslocalisation

SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT03984448

Ouvrir le site du centre

Essais cliniques associés

17

Molécule	Indication / population	Phase	NCT	Titre	Statut
Biospecimen Collection	Cancer	Phase 3	NCT07097142	Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study	RECRUITING
Bevacizumab	Cancer	Phase 3	NCT07198074	Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer	RECRUITING
Biospecimen Collection	Cancer	Phase 3	NCT04269902	Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study	RECRUITING
Biospecimen Collection	SEP	Phase 2/3	NCT03984448	Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas	ACTIVE_NOT_RECRUITING
Biospecimen Collection	Cancer	Phase 3	NCT06058377	Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	RECRUITING
Azacitidine	Cancer	Phase 2	NCT05554406	Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)	RECRUITING
Acalabrutinib	Cancer	Phase 2	NCT04115631	A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma	ACTIVE_NOT_RECRUITING
Biopsy Procedure	Cancer	Phase 2/3	NCT04628767	Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer	RECRUITING
Biospecimen Collection	Cancer	Phase 3	NCT06337318	Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma	RECRUITING
Biospecimen Collection	Cancer	Phase 3	NCT05675410	A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab	RECRUITING
Biospecimen Collection	Cancer	Phase 3	NCT05256225	Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma	RECRUITING
Biospecimen Collection	Cancer	Phase 3	NCT04267848	Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])	RECRUITING
Biospecimen Collection	Cancer	Phase 3	NCT06524544	A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer	RECRUITING
Biospecimen Collection	Cancer	Phase 2/3	NCT06203600	Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial	RECRUITING
Anastrozole	Cancer	Phase 3	NCT07391774	Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial	RECRUITING
liposomal doxorubicin	Cancer	Phase 2	NCT01078441	Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant	TERMINATED
Bevacizumab	Cancer	Phase 2	NCT00861705	Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery	COMPLETED